dynavax.com - Wutah pendapatan taun lumaku DVAX

Logo perusahaan publik Dynavax Pharma (DVAX)

Dynavax Technologies (DVAX) maintains high margins by attracting top specialists through premium bonuses and stock options. This chart of LTM sales volume changes year-over-year clearly captures the trend, where the parameter value reaches 27.20. Company revenues rely on the commercialization of hepatitis B vaccines, while the modernization of biopharmaceutical complexes guarantees stable production without downtime.

Dynavax Technologies Corporation (DVAX) - Wutah dodolan YoY (TTM) saka 11.02.2024 nganti 21.02.2026

dynavax.com (DVAX) - rincian metrik lan laporan keuangan

- rega saham lan prakiraan rega para ahli:
Pambiji fundamental perusahaan:Dynavax Pharma - DVAX
Produk sing diprodhuksi Dynavax Technologies

Dynavax Technologies (DVAX) dominance in the Hepatitis B vaccination segment is driven by the uniqueness of HEPLISAV-B and its shortened dose course, which directly stimulates commercial demand. By analyzing the year-over-year product sales volume dynamics over the TTM, an investor assesses the revenue expansion rate on a rolling year basis, allowing for the timely identification of the business's transition from stagnation to an active growth phase and preventing overpayment for the asset.